+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
FEMALE
ID07508306

Evaluating Patent Blue Dye Sentinel Lymph Node Biopsy Compared to Full Lymphadenectomy in Early-Stage Ovarian Cancer Surgical Care

Led by Faculty of Medicine of Tunis · Updated on 2026-09-10

30

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the use of sentinel lymph node biopsy with patent blue dye in patients with early-stage ovarian cancer FIGO stage I or II. The standard treatment involves complete surgery including removal of the uterus, ovaries, and lymph nodes, but this extensive surgery carries risks such as blood loss and long recovery. The study investigates if using the sentinel lymph node biopsy technique can reduce these risks by identifying the first lymph node that cancer may spread to, potentially minimizing the extent of lymph node removal. During surgery, the patent blue dye will be injected into specific ligaments near the ovarian tumor. After waiting 15 minutes, surgeons will identify and remove the sentinel lymph nodes from pelvic and para-aortic areas for pathological analysis. Then, the standard complete surgery including full lymphadenectomy will be performed. The study compares the results of sentinel lymph node biopsy with those of the complete lymphadenectomy to assess feasibility and accuracy. Participants will undergo preoperative imaging and biomarker tests, followed by the surgical procedure where sentinel lymph node mapping and complete lymphadenectomy take place. Data collected include patient demographics, surgical details, tumor characteristics, and postoperative outcomes such as complications and hospital stay. Researchers will measure technical feasibility, diagnostic accuracy, and anatomical distribution of sentinel nodes, monitoring pathology results within four weeks post-surgery. The study is observational and aims to improve surgical care while minimizing morbidity.

CONDITIONS

Brief Title

Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity

Research Team

M

Mohammed Amine Hannachi, Assistant professor

K

Khaled Neji, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here